Kolber-Postepska B, Zebrowska-Lupina I, Markiewicz M, Horubała-Bielak G
Kardiol Pol. 1989;32(3):121-30.
Authors studied effect of captopril on serum kininogen and prekallikrein concentrations, as well as on plasma renin activity (PRA) in patients with primary hypertension. The control group consisted of 18 healthy persons, 5 patients were in I, 12 in II and 8 in III WHO class. Monotherapy with 150 mg per day of captopril had been performed for 3 weeks. Patients were 3 times examined: 1--before therapy, 2--after 24 hours of treatment, 3--after 3 weeks of captopril therapy. It was proved, that captopril lowers arterial pressure with coexisting PRA increase and induces changes in kinins system such as: decrease of kininogen+ concentration and increase of serum prekallikrein level in comparison with their pretreatment values. Maximum PRA increase and blood pressure decrease were observed after 24 hours of captopril administration, whereas changes in kinins system were taking place during the whole observation period. Presented studies indicate that antihypertensive action of captopril is related to Renin-Angiotensin-Aldosterone System as well as to plasma kinins one.
作者研究了卡托普利对原发性高血压患者血清激肽原、前激肽释放酶浓度以及血浆肾素活性(PRA)的影响。对照组由18名健康人组成,WHO分级中I级有5例患者,II级有12例,III级有8例。每天服用150毫克卡托普利进行单一疗法,持续3周。对患者进行了3次检查:1次在治疗前,2次在治疗24小时后,3次在卡托普利治疗3周后。结果证明,卡托普利在降低动脉血压的同时使PRA升高,并引起激肽系统的变化,如与治疗前值相比,激肽原浓度降低,血清前激肽释放酶水平升高。在服用卡托普利24小时后观察到PRA升高和血压降低的最大值,而激肽系统的变化在整个观察期内都在发生。目前的研究表明,卡托普利的降压作用与肾素-血管紧张素-醛固酮系统以及血浆激肽系统有关。